Opening an aesthetic clinic in Singapore, decoded.
The high-margin dream of medicine — and a quietly brutal one. The gross margins on a laser or a syringe are enormous, the demand is real and growing, and a state licence keeps the salons out. But the same machine you bought for six figures dates in a few years, the “next platform” is always launching, the doctor takes a slice of every dollar, and at the crowded end it's a price war. Here is the picture the clinic brochures skip — what the SMC actually lets a doctor do, the licences in order, the high-gross / leaky-net economics, and the device treadmill underneath it all.
100%
self-pay — no Medisave or insurance
S$360
the HCSA clinic licence (the cheap part)
78%
of a device maker's sales are the machine, not refills
~S$50k–300k
per machine — and you need several
The MOAT Score: is an aesthetic clinic worth building?
Before the details, our one-number read. The MOAT Score grades a sector's economic quality on the value-investing lens of Graham, Buffett and Munger — four pillars (Margin, Operating moat, Appetite, Treadmill), each out of 25. At 54/100 (C), an aesthetic clinic lands in a completely different place from its sibling, the dental clinic (which we score 68): the gross margins are fatter, but the moat is narrower, the demand is fully discretionary, and a device treadmill runs underneath. A real business — with a real edge.
Needs a real edge
Only with a real edge.
How the score is built
The MOAT Score sums four pillars — each scored 0–25 — from the value-investing lens of Graham, Buffett and Munger. No black box: here is the working.
Margin
16/25Does the average operator actually keep money — real net margin and return on the capital tied up?
This sector: the margin engine: gross margins on injectables and lasers run high (a service at ~70%Global or regional figure — not Singapore-specificUS med-spa benchmark (KMF/AmSpa)US/international proxy; no clean SG clinic-level gross-margin figure is published. Illustrative of the high-gross shape, not an SG measurement. gross; near-zero marginal cost on a laser shot) — but net is leaky: marketing at 8–15% of revenue, a doctor commission up to ~30%, prime rent, and fast device depreciation. No listed SG pure-play exists to anchor it.
Buffett 1979 — “a high earnings rate on equity capital… without undue leverage”; 1986 owner earnings.
Operating moat
13/25Pricing power and a durable competitive advantage — can a typical operator raise prices and have customers shrug?
This sector: a real but narrow licence moat: a salon legally cannot inject or run a medical laser, and a GP needs a Certificate of Competence for Table-1 procedures — but it's the same generic clinic licence as any GP, the doctor pool is large, and switching costs are weak. The commodity tier is a price war. Clearly below dental's statutory moat.
Buffett, FCIC 2010 — pricing power is “the single most important decision”; 1991 franchise; 2007 moat.
Appetite
14/25Demand durability — steady, recession-resistant repeat demand vs fragile, discretionary or faddish.
This sector: 100% discretionary, self-pay — no Medisave, MediShield or insurance at all (cosmetic care was explicitly excluded from MediShield Life from 1 Mar 2021). A genuine, growing “tweakment” wave, but fashion- and sentiment-exposed, and the first spend cut in a downturn.
Graham, Security Analysis Ch.2 — inherent stability “derives from the character of the business”.
Treadmillinverted · less is better
11/25Capital intensity and structural drag — rent, churn, fashion, discounting. Scored inverted: less treadmill, more points.
This sector: the device-capex obsolescence treadmill: six-figure machines that date fast, constant “latest platform” pressure, and proprietary locked consumables — the razor-blade model (78% / 22%SourceInMode FY2025 results (Nasdaq: INMD), Feb 2026 capital vs consumables) — plus a customer you re-acquire with heavy marketing. Below dental's 13.
Buffett 2007 — “the worst sort of business… requires significant capital… Think airlines.”
M + O + A + T, out of 100
The MOAT Score is a transparent SGAI judgement on a sector’s economic quality through a value-investing lens — not a verdict on any individual business, and not a comment on an owner-operated livelihood (a sector can score low on capital returns yet work as a job).
The read: a fat-margin service strapped to a depreciating machine
Start with what makes aesthetics seductive. The gross margin is the best in clinical medicine. A vial of botulinum toxin a clinic buys for a few hundred dollars treats several patients; a laser shot has almost no marginal cost at all — the cost was the machine. So once a treatment room is busy, each additional session is mostly profit. That, plus demand that grows every year, is why so many doctors are drawn in. It is a genuinely better gross-margin business than a dental clinic.
But the net margin is a different animal, and three things eat it. First, the machine itself. An aesthetic clinic is a device business wearing a white coat: the lasers, the HIFU platform, the RF microneedling rig, the body-contouring system each cost tens to hundreds of thousands of dollars, and a serious clinic runs several, not one. Worse, they date. A new platform launches every year, depreciation is fast, and the marketing pressure to always have the “latest” machine is relentless. The device makers know it: at InMode, the company behind Morpheus8, fully 78% of 2025 revenue was the machines and only 22% the consumables — the razor-and-blades model, and the clinic is buying the razor again every few years.
Second, the doctor. Like the dental associate split, the doctor who performs the work takes a slice — structured in Singapore as base plus commission, the commission running up to about 30% of revenue for a senior doctor. Third, and unusually for medicine, marketing. A dental practice grows on recall and referral; an aesthetic clinic competes for a discretionary customer who shops around, so it spends an estimated 8–15% of revenue on marketing — a line a normal clinic barely has. Fat gross, three hungry mouths, thin-to-good net depending entirely on which end of the market you're at.
And that is the real split. Aesthetics is two businesses wearing one name. At the commodity end — standard botox, a pico-laser session, fat-freezing — the drug and the device are the same everywhere, switching costs are nil, and chains compete on price with “from S$16 a unit” and disguised trial deals. One Singapore aesthetic doctor put it plainly: the field has become “increasingly commoditised, with price wars and the race to the bottom.” At the other end, a celebrity-backed clinic with a sought-after doctor caps its patient intake and sustains multiples of the commodity price on scarcity and reputation. Same treatment, a 3–10× price gap. The whole game is deciding which clinic you are — and the licence, which you'll get, decides nothing.
One treatment, two markets: the price-maker gap
The clearest proof that aesthetics is two businesses: the SAME procedure spans a 3–10× range depending on whether you're buying a commodity session or a celebrity-doctor's brand. Ultherapy below, from real SG clinic price lists.
- Pico laser — commodity / trialS$200
price-taker end; "from S$48 nett" promos undercut even this
- Botox — per area (value GP tier)S$300
"from S$16/unit" — the race to the bottom
- Ultherapy / HIFU — value endS$720
generic HIFU competes hard on price
- Dermal filler — per syringeS$1000
- Ultherapy — premium / brandedanchorS$4320
same machine, brand-name clinic — the price-maker tier
- Thread lift — premium / per areaS$5000
celebrity-doctor pricing on scarcity
Source: SGAI triangulation of SG clinic price lists (V Medical, SL Aesthetic, AURA, IDS and others), 2026 — indicative ranges, incl. GST; injectable/brand prices cannot legally be advertised, so treat as approximate
The map: a real market — and the “market size” number that mixes machines with treatments
Here is the trap, and it is the exact same one as the dental report. There is no clean, transparent Singapore market-size figure for aesthetics — only paywalled aggregators — and the numbers that circulate quietly mix up two different things. The devices market (the lasers and machines clinics buy) is one figure; ~US$361MShaky figure — treat with cautionData Bridge — SG Medical Aesthetics (devices/equipment), 2024This is the EQUIPMENT/devices market — capital goods clinics buy — NOT what clinics bill patients. Paywalled aggregator, single source, methodology unverified. Same trap as the dental 'US$88.7M devices' number. in 2024. The services market (what clinics actually bill patients) is a different, larger figure — ~US$604MShaky figure — treat with cautionData Bridge — SG Aesthetic Services, 2024Aggregator estimate for the services/procedures market; paywalled, single-source, methodology unverified. The widely-mis-cited 'US$1,188M' is this report's 2032 FORECAST, not a 2024 value.. Quote the wrong one and you understate the clinic market by ~40%. And ignore the “US$1,188MShaky figure — treat with cautionaggregator 2032 forecast mis-cited as 2024This is a 2032 FORECAST, repeatedly mis-quoted as a current 2024 figure. Do not use it as today's market size.” you'll see passed off as today's size — it's a 2032 forecast.
The structurally important facts are different from dental in one big way: there is no clean listed proxy. Dentistry has Q&M (SGX-listed, audited) as a window into clinic economics. Aesthetics has none — the closest, Singapore Medical Group, was delisted in January 2023, and even when listed it bundled aesthetics into a “diagnostic & aesthetics” segment. The market is private, fragmented, owner-operated — and the consolidation that exists is tiny and foreign-led.
~US$604M
SG aesthetic SERVICES market
Data Bridge 2024 estimate — flagged, aggregator
~US$361M
SG aesthetic DEVICES market
equipment, NOT clinic billings — don't conflate
None
clean SGX-listed pure-play proxy
unlike dental's Q&M; SMG delisted Jan 2023
S$7.8M
paid for a 21-outlet aesthetic group (2024)
SBC → AHH — a thin-multiple, fragmented signal
The market everyone quotes mixes two different things
The honest read: the 'aesthetic market' is two numbers — the machines clinics buy, and the treatments they bill. They are not the same, and the larger forecast figure that circulates is a 2032 projection, not today.
Devices (2024)—equipment clinics buy — the capex
Services (2024)—what clinics actually bill patients
2032 forecast—a projection — often mis-quoted as "now"
Stale: mis-cited as a current figure
Source: Data Bridge Market Research, SG aesthetic devices vs services reports (2024 base, 2032 forecast). All paywalled, single-source, methodology unverified — treat as indicative, flagged.
The players: who you're really studying
The market splits by positioning, not scale: celebrity/premium brands that hold pricing power, value chains that compete on price, and a long tail of owner-operated single-doctor clinics. None publish revenue — they are private companies — so every “scale” signal below is a location count or a self-reported claim, flagged as such.
Four ways to compete in Singapore aesthetics
| Player / model | Model | Real moat? | Pricing power? | Signal |
|---|---|---|---|---|
| SW1 ClinicPremium / celebrity (Dr Low Chai Ling) | Exclusivity-led; cosmetic derm + surgery | Caps new-patient intake; where the price-maker margin lives | ||
| Halley / Cutis / Mizu / AstiqueOwner-doctor premium independents | Single-clinic, brand-around-the-doctor | The bulk of the quality market — niche + reputation | ||
| V Medical / value chainsMulti-outlet, price-led | "From S$16/unit", trial deals, volume | The commodity tier — the race to the bottom | ||
| IDS ClinicVertically integrated (clinic + skincare line) | Aesthetics + own cosmeceutical brand | The product line is the durable asset, not the room | ||
| SBC Medical / AHHForeign-listed consolidator (Nasdaq: SBC) | Roll-up: Chelsea, Gangnam Laser, SkinGo! | S$7.8M for 21 outlets — a thin-multiple buyer |
SW1 Clinic
Premium / celebrity (Dr Low Chai Ling)
- Model
- Exclusivity-led; cosmetic derm + surgery
- Real moat?
- Pricing power?
- Signal
- Caps new-patient intake; where the price-maker margin lives
Halley / Cutis / Mizu / Astique
Owner-doctor premium independents
- Model
- Single-clinic, brand-around-the-doctor
- Real moat?
- Pricing power?
- Signal
- The bulk of the quality market — niche + reputation
V Medical / value chains
Multi-outlet, price-led
- Model
- "From S$16/unit", trial deals, volume
- Real moat?
- Pricing power?
- Signal
- The commodity tier — the race to the bottom
IDS Clinic
Vertically integrated (clinic + skincare line)
- Model
- Aesthetics + own cosmeceutical brand
- Real moat?
- Pricing power?
- Signal
- The product line is the durable asset, not the room
SBC Medical / AHH
Foreign-listed consolidator (Nasdaq: SBC)
- Model
- Roll-up: Chelsea, Gangnam Laser, SkinGo!
- Real moat?
- Pricing power?
- Signal
- S$7.8M for 21 outlets — a thin-multiple buyer
The missing anchor: there is no Q&M of aesthetics
In the dental report, Q&M's audited accounts let us read exactly what a clinic earns. Aesthetics has no such window. The one listed proxy, Singapore Medical Group, went private in January 2023 (taken out at S$0.40 a share), and it only ever reported a bundled “diagnostic & aesthetics” segment — which it did call its higher-margin division. The clearest recent transaction tells its own story: in November 2024, Nasdaq-listed SBC Medical bought the 21-outlet Aesthetic Healthcare Holdings for about S$7.8M. That is a thin price for 21 clinics — a fragmented, low-multiple market where individual clinics aren't worth much unless a real brand sits on top.
The customer: every dollar is discretionary — and entirely their own
This is the sharpest contrast with dental. Some dental work is Medisave-claimable; aesthetics is 100% out of pocket — cosmetic procedures are not covered by Medisave or MediShield Life, and were explicitly excluded from 1 March 2021 (MOH has even taken enforcement action against doctors miscoding cosmetic work as claimable). That makes the customer a pure discretionary spender: affluent, appearance-conscious, and price-sensitive at the commodity end. Demand is genuinely broadening — the “tweakment” has normalised, and male patients are a fast-growing share — but it remains the first line a household cuts when money tightens.
Who buys medical aesthetics in Singapore
Indicative segmentation — there is no official MOH breakdown of aesthetic patients, so this is SGAI's synthesis of clinic-reported patient mixes and the one peer-reviewed SG survey (a youth cohort). Directional, not a census.
- Women 25–45 (anti-ageing, skin, tweakments)48%the core: botox, fillers, skin-boosters, pico-laser
- Women 45+ (lifting, skin laxity, devices)22%higher-ticket HIFU/RF/thread work
- Men (the fast-growing slice)18%"Brotox", jawline, hair — clinic-reported surge, flag as directional
- Younger (acne scars, pigment, "prejuvenation")12%SG youth survey: ~2.5–3% had a procedure; ~9% open to it
Source: SGAI synthesis of clinic-reported patient mixes + the SMJ youth survey (PMC4294091); no official SG aesthetic-patient demographic exists. Shares are indicative of the structure, not a measured split.
The tailwind: appearance normalised
The drivers are real: K-beauty and filtered-selfie culture, the de-stigmatising of “a little work”, and a rising male market. But unlike dental's aging-population wave — a slow, certain demographic driver — aesthetic demand is fashion- and sentiment-led. It can grow fast and it can soften fast. Treat it as a wave to ride with discipline, not a structural certainty.
The leak: Korea, Bangkok, Johor
Price-driven aesthetic travel out of Singapore — to Korea and Bangkok for big procedures, to Johor Bahru for cheaper injectables — is real and pressures the commodity tier. (Treat the specific “30–50% cheaper” figures as unverified travel-blog copy.) It rewards clinics that compete on trust, safety and complex care that doesn't travel well — and punishes those competing only on the price of a standard syringe.
The economics: the margin is fat at the top of the P&L and thin at the bottom
The licence is trivial — S$360 for the HCSA clinic licence, plus S$550/yr for the doctor's Practising Certificate. The money goes into the build-out and, above all, the machines: a single laser runs roughly S$50,000–300,000, and a credible clinic needs several platforms, so device capex alone can clear S$0.5–1.5M before fit-out. Then the operating dollar gets shared three ways no other clinic shares it: the doctor's commission (up to ~30%), unusually heavy marketing (8–15% of revenue), and device depreciation on machines that date in a few years. High gross, hungry middle, variable net.
All-in cost to open a doctor-led aesthetic clinic
Medical-grade fit-out in a prime location (~S$200–500 psf), plus the devices — the biggest and most variable swing — plus licensing, pre-opening marketing and working capital. A lean single-device clinic can start in the low-to-mid six figures; a device-heavy Orchard build runs past S$1M. No published SG 'all-in' figure exists — this is an SGAI build from SG fit-out rates and international device-capex proxies.
Source: SGAI build from SG medical fit-out psf (contractor guides) + international device-capex ranges; no sourced single SG 'cost to open' figure exists (flag: estimate)
Where the aesthetic dollar goes
A typical SG aesthetic clinic, modelled per S$100 of revenue. The gross margin is high — consumables are cheap — but the doctor's cut, the marketing load and device depreciation are what separate a fat-net brand clinic from a thin-net commodity one.
- Doctor commission−25%75% left
base + commission; up to ~30% for a senior doctor (the aesthetic "associate split") · SG job-ad commission ranges — no salary survey
- Marketing−12%63% left
unusually heavy for a clinic — a discretionary customer must be won, not recalled · SG agency guidance (8–15% of revenue) — flag
- Rent + occupancy−12%51% left
prime medical clusters (Paragon/Camden) — ~S$19–21 psf asking · SG listings (CommercialGuru/99.co) — flag
- Device depreciation−12%39% left
six-figure machines that date fast — the obsolescence treadmill · SGAI calc on international device-capex proxies
- Support staff + CPF−14%25% left
therapists, nurses, reception, consultants; CPF 17% on top · SG estimate — no SG ratio published
- Consumables (drug, filler, proprietary tips/transducers)−9%16% left
cheap as a % of a session — the source of the high gross margin · International wholesale proxy vs SG retail price — flag
- Other fixed (utilities, licences, software, insurance)−8%8% left
What the owner actually keeps
Verdict: A thin 8% — survivable, not comfortable; one bad assumption flips it negative.
Illustrative model: no SG aesthetic clinic publishes a P&L (no listed pure-play), so the doctor cut, marketing and device-depreciation lines are SGAI estimates built from SG job ads, agency guidance and international device-capex proxies — flagged where used. The net is wide: thin at the commodity end, healthy at the brand/price-maker end. Not financial advice.
Aesthetic clinic / medical aesthetics
Would a value investor own the average operator here?
A value investor would own a brand-name aesthetic clinic — not the average one. The gross margins are excellent and a licence keeps salons out, but the moat is narrow, demand is fully discretionary, and a device-capex + marketing treadmill turns the commodity tier into a price war.
A sought-after celebrity-doctor clinic sustains 3–10× the commodity price on scarcity and reputation; standard botox and laser are fiercely competed. The average operator is closer to taker than maker.
Buffett, FCIC 2010 — pricing power is “the single most important decision”
A real but narrow barrier: HCSA clinic licence + an SMC Certificate of Competence (a salon cannot inject or run a medical laser) — but it is the same generic clinic licence as any GP, the doctor pool is large, and switching costs are weak.
Buffett 1991 — a franchise requires no close substitute; 2007 — an enduring moat
High gross, but heavy device capex that depreciates fast means ROIC depends on filling the machines before they date — wide between a brand clinic and a commodity one.
Buffett 1979 — a high earnings rate on capital, unleveraged
Six-figure machines, several of them, on an obsolescence clock — and to keep marketing you must keep buying the "latest".
Buffett 2007 — the worst business needs much capital, earns little
100% self-pay, no insurance rail at all; a real growing wave, but fashion- and sentiment-exposed and the first spend cut in a downturn.
Graham, Security Analysis Ch.2 — inherent stability is qualitative
A genuine brand around a credentialled, sought-after doctor (the price-maker tier), capital discipline on devices (buy the payback, not the hype), and a defensible niche — not commodity botox at the bottom of a price war.
Assessment uses the value-investing lens on SG aesthetic unit economics (2022–2026). No listed SG pure-play exists, so cost ratios are SGAI estimates + international proxies, flagged where used. A lens on economic quality, not a verdict on an owner-operated livelihood.
Model your own machine — the whole game is paying it back before it goes obsolete:
Device payback
10.3 mo
comfortably inside its life · ~617 sessions
Monthly net (this device)
−S$2,515
after depreciation
Obsolescence horizon
48 mo
paid back in time
Verdict: The device pays back in time, but the clinic is still losing money monthly once depreciation, the doctor cut and marketing are counted. Fill the room or lift the mix.
Illustrative model on SG patient-price observations + international device-capex proxies (2024–2026). Singapore publishes no per-clinic aesthetic P&L; machine prices are sold by quote, so capex is an international proxy and the doctor cut is modelled on SG job-ad commission ranges. Depreciation is straight-line over the obsolescence horizon; the doctor's and marketing cut are modelled as variable. A starting frame, not financial or clinical advice.
How to actually open one (and what you're actually allowed to do)
Two things gate an aesthetic clinic: the premises licence, and — the part most people get wrong — what the SMC actually permits a doctor to perform. Get the second one current, because the rules everyone quotes are out of date.
What a doctor is permitted to do (the real framework)
The governing document is the SMC Guidelines on Aesthetic Practices for Doctors (2016 Edition) — still in force (the SMC page was last updated February 2026). Procedures sit in two tables:
- Table 1 — a trained GP may perform, with a Certificate of Competence (COC) verified by the Aesthetic Practice Oversight Committee (APOC): botulinum toxin, dermal fillers (face, neck, hands only), most lasers and IPL, chemical peels, radiofrequency/ultrasound skin tightening (HIFU), thread lifts, and cryolipolysis-type body contouring.
- Table 2 — reserved to the relevant specialists (mostly plastic surgeons): blepharoplasty, rhinoplasty, facelift, brow lift, facial implants, breast and abdominal surgery. A GP may not do these at all.
- “List A / List B” is dead. List B (mesotherapy, carboxytherapy) was abolished from 1 March 2015. Any guide still using that terminology is citing a pre-2016 regime — a fast way to spot stale advice. Note too: aesthetic practice is not a recognised specialty, so titles like “aesthetic physician” are not permitted.
The approval stack, sequenced
- SMC registration + Practising Certificate (S$550/yr) — the doctor must be registered to practise.
- Certificates of Competence — for each Table-1 procedure the doctor will perform (the real aesthetic-specific gate; courses via the accredited providers, verified by APOC).
- URA change-of-use — the premises must be approved for clinic use. Gate 1.
- SCDF fire safety — plans via a Qualified Person → Fire Safety Certificate. Gate 2.
- HCSA Outpatient Medical Service licence — apply via the HALP portal; appoint a Clinical Governance Officer (SMC-registered; a family physician/specialist or with ≥5 years' practice). S$360/MOSD (+S$900 if you offer liposuction as a specified service). HCSA licences renew on a 2-year cycle.
- By concept: NEA registration for any laser/irradiating apparatus, controlled-drugs/poisons handling (HSA), signage approval.
The trap most founders miss: the advertising rules
The marketing playbook that works for a normal consumer business is largely illegal for a Singapore aesthetic clinic — which is brutal, because aesthetics liveson marketing. Under the Healthcare Services (Advertisement) Regulations 2021 and the SMC Ethical Code, a clinic cannot use before-and-after photos, patient testimonials, time-limited discounts or Groupon-style deals, free-trial lead magnets, superlative (“best/most advanced”) claims, guaranteed outcomes, or influencer endorsements with free treatments. MOH reiterated in January 2024 that non-medical influencers cannot advertise licensable aesthetic services; penalties reach S$20,000 and/or 12 months' jail. The 2022 rules effectively ended the open daily-deal discounting of the early 2010s — it survives only as disguised “nett price” and package deals. Compliant growth runs on credentials, genuine educational content, organic reputation and referral. Build the plan around that from day one.
Where a new clinic actually wins
The commodity tier is a price war you don't want to win. The clinics that earn a real return don't compete on the price of a standard syringe — they build something the race to the bottom can't copy.
A brand around a credentialled doctor
The price-maker tier is real: a sought-after, genuinely qualified doctor sustains multiples of the commodity price on trust and scarcity. The doctor IS the moat — invest in credentials and reputation, not the cheapest deal.
Buy the payback, not the hype
The device treadmill kills clinics that buy the "latest" machine to market it. Buy a platform that pays back inside its useful life at realistic volume — and resist the per-cycle, locked-consumable traps that make the maker rich and you poor.
Own a clinical niche
Acne scars, pigment, hair loss, complex skin, ethnic-skin laser safety — defensible expertise a value chain can’t fake. Depth beats a menu of everything-for-everyone.
Vertical integration (a product line)
The IDS model: an owned cosmeceutical/skincare line is a durable, recurring-revenue asset that travels beyond the treatment room and isn’t a price-war commodity.
The under-served male market
Men are the fastest-growing slice and badly served by a market built for women. A clinic built credibly for male patients addresses real, growing, less price-shopped demand.
The honest AI/tech edge
The certain wins are operational: smart booking and no-show reduction, skin-analysis imaging for consults, and demand/inventory forecasting on expensive consumables. Treat AI skin-diagnosis as a consult aid, not a differentiator — and never as a substitute for the doctor the rules (and the moat) require.
Questions founders ask
What aesthetic procedures can a GP (non-specialist doctor) perform in Singapore?
Singapore governs this through the SMC Guidelines on Aesthetic Practices for Doctors (2016 Edition, still in force — the page was last updated February 2026). Procedures sit in two tables. Table 1 procedures — botulinum toxin, dermal fillers (face, neck and hands only), most lasers and IPL, chemical peels, radiofrequency/ultrasound skin tightening (HIFU), thread lifts and cryolipolysis-type body contouring — can be performed by a trained GP, provided they hold a Certificate of Competence (COC) verified by the Aesthetic Practice Oversight Committee (APOC). Table 2 procedures — blepharoplasty (eyelid surgery), rhinoplasty, facelifts, breast and abdominal surgery — are reserved to the relevant specialists (mostly plastic surgeons). The old "List A / List B" terminology is out of date: List B (mesotherapy, carboxytherapy) was abolished from 1 March 2015, so any guide still using it is citing a pre-2016 regime.
What licence do I need to open an aesthetic clinic in Singapore?
There is no separate "aesthetic clinic" licence. A doctor-led aesthetic clinic is licensed as a generic Outpatient Medical Service (OMS) under the Healthcare Services Act (HCSA) — the same class as an ordinary GP clinic — applied for via the HALP portal, with a Clinical Governance Officer who is an SMC-registered doctor (a family physician/specialist, or with at least five years of practice). The OMS licence fee is S$360 per Mode of Service Delivery; a specified service such as liposuction adds S$900 (about S$1,260 total). The doctor must hold a valid SMC Practising Certificate (S$550/year from 1 February 2025) plus the relevant Certificates of Competence for the procedures performed. The licence is the cheap part — the real cost is the build-out and the devices.
Are aesthetic clinics profitable in Singapore, and what are the margins?
The gross margins are genuinely high — a laser, botox or filler session bills a multiple of its consumable cost, and a laser shot has almost no marginal cost — which is why aesthetics is one of the higher-margin things a doctor can do. But there is no clean Singapore net-margin figure: no aesthetic clinic is a listed pure-play (unlike dental, where Q&M is a public proxy), and the segment numbers that did exist — Singapore Medical Group called its diagnostic-and-aesthetics arm its "higher margin" division before it delisted in January 2023 — bundle diagnostics in. What erodes the net is unusual for medicine: marketing runs an estimated 8–15% of revenue (far above a normal clinic), the doctor takes a commission of up to about 30%, prime-district rent, and fast device depreciation. The economics are good at the brand/price-maker end and thin in the commoditised "race to the bottom" tier.
Can an aesthetic clinic advertise before-and-after photos or discounts in Singapore?
No. Aesthetic advertising is heavily restricted under the Healthcare Services (Advertisement) Regulations 2021 (binding the clinic) and the SMC Ethical Code and Ethical Guidelines (binding the doctor). Before-and-after photos, patient testimonials, time-limited discounts and Groupon-style deals, free-trial lead magnets, superlative claims ("best", "most advanced"), guaranteed outcomes and influencer endorsements with free treatments are all prohibited. MOH reiterated in January 2024 that non-medical influencers cannot advertise licensable aesthetic services; penalties reach S$20,000 and/or 12 months in jail. The 2022 rules effectively ended the open daily-deal discounting of the early 2010s — it has been pushed into disguised "nett price" and multi-session packages instead.
Want a report like this for your company or sector?
Tell us what you're trying to figure out. We'll build you a Deep-Context report — the same depth, focused on your business.
About this report. Built with SGAI's Deep-Context Engine — human-directed, AI-accelerated. Figures draw on the Singapore Medical Council (the Guidelines on Aesthetic Practices for Doctors, 2016 Ed., and the Practising Certificate fee), the HCSA licensing framework (Outpatient Medical Service), MOH (incl. the January 2024 advertising guidance and the MediShield Life cosmetic exclusion), the delisted Singapore Medical Group's last filings, SBC Medical's (Nasdaq) acquisition disclosures, InMode's FY2025 results, and SG clinic price lists. Singapore publishes no clean per-clinic aesthetic unit economics and has no listed pure-play, so cost ratios and device-capex are SGAI estimates and international proxies — flagged where used. Verify fees, the current SMC guidelines and regulatory steps with each agency before acting; this is not financial, legal or clinical advice.
We're not a grant office — we build AI and intelligence for Singapore SMEs. Talk to us.